Correction to: BMC Cancer 21, 1207 (2021)
https://doi.org/10.1186/s12885-021-08881-7
Following publication of the original article [1], it was identified that due to typesetting mistakes, an unfinalized version of the article were published. The following changes have been implemented.
-
1)
The corresponding author’s email address has been corrected: Philippe.Thompson-Leduc@analysisgroup.com
-
2)
In table 1, note 2, the full reference is: Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9. https://doi.org/10.1200/JCO.2015.61.2267
-
3)
In table 2, note 3, the full reference is: Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://doi.org/10.1056/NEJMoa1607751
-
4)
In table 3, note 1, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https://doi.org/10.1016/S1470-2045(16)30206-6
-
5)
In table 4, note 2, the full reference is: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. https://doi.org/10.1016/S1470-2045(16)30206-6
-
6)
In the section, Treatment patterns of first daratumumab-based regimen, paragraph three: The text should not have been in bold typeface.
-
7)
In the section, Treatment patterns of first daratumumab-based regimen, paragraph three: “3.3 Clinical outcomes” Was removed from the end of the paragraph.
-
8)
In the abbreviations list, “3 L: Third line or later” was updated to “3 L+: Third line or later”
These corrections were typesetting errors and do not influence the results of this article. The publishers apologise for this error. The original article [1] has been updated.
Reference
Atrash S, Thompson-Leduc P, Tai, MH., et al. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021;21:1207. https://doi.org/10.1186/s12885-021-08881-7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Atrash, S., Thompson-Leduc, P., Tai, MH. et al. Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer 21, 1291 (2021). https://doi.org/10.1186/s12885-021-09015-9
Published:
DOI: https://doi.org/10.1186/s12885-021-09015-9